TZP-102

DB16129InvestigationalSmall molecule

TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).

Mechanism: Pharmacologically active on Growth hormone secretagogue receptor type 1
Curator reviewed
Formula / weight: C₂₈H₄₄N₄O₄ · 500.684 g/mol (avg)
Code names: TZP-102

Resolves to

Compound

UNII9NFY3MS3SLCAS1008993-65-4

Structure

InChIKeyHIIMPSTXUQUYOO-KRANKMRJSA-NSMILESCC(C)C[C@H]1NC(=O)[C@@H](C)N(C)C(=O)[C@@H](NC[C@@H](C)OC2=C(CC[C@H](C)NC1=O)C=CC=C2)C1CC1

Targets

Q92847GHSR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with TZP-102, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account